Skip to main content

Table 4 The association of clinicopathological parameters with overall, cancer-specific and disease-free survival in patients

From: Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model

Characteristics Total Overall survival P* Cancer-specific survival P* Disease-free survival P*
n(%) 389 n(%) of patients with death (n = 270) n(%) of patients with death (n = 235) n(%) of patients with recurrence (n = 302)
Sex Female 107 (27.5%) 72 (26.7%) 0.518 66 (28.1%) 0.629 80 (26.5%) 0.279
Male 282 (72.5%) 198 (73.3%) 169 (71.9%) 222 (73.5%)
Age (years) <65 185 (47.6%) 111 (41.1%) 0.000 98 (41.7%) 0.000 132 (43.7%) 0.001
≥65 204 (52.4%) 159 (58.9%) 137 (58.3%) 170 (56.3%)
Alcohol Yes 73 (18.8%) 48 (17.8%) 0.437 43 (18.3%) 0.439 55 (18.2%) 0.601
No 316 (81.2%) 222 (82.2%) 192 (81.7%) 247 (81.8%)
Tobacco Yes 72 (18.5%) 56 (20.7%) 0.152 49 (20.9%) 0.125 61 (20.2%) 0.326
No 317 (81.5%) 214 (79.3%) 186 (79.1%) 241 (79.8%)
Family history Yes 15 (3.9%) 9 (3.3%) 0.557 8 (3.4%) 0.554 14 (4.6%) 0.005
No 374 (96.1%) 261 (96.7%) 227 (96.6%) 288 (95.4%)
Histological type papillary 19 (4.9%) 10 (3.7%) 0.163 9 (3.8%) 0.249 11 (3.6%) 0.041
tubular 81 (20.8%) 53 (19.6%) 45 (19.1%) 59 (19.5%)
   poorly differentiated 203 (52.2%) 148 (54.8%) 126 (53.6%) 165 (54.6%)
  mucinous 57 (14.7%) 37 (13.7%) 35 (14.9%) 43 (14.2%)
   signetring cell 29 (7.4%) 22 (8.1%) 20 (8.5%) 24 (7.9%)
Tumor grade G1-G2 214 (55.0%) 139 (51.5%) 0.061 127 (54.0%) 0.168 159 (52.6%) 0.044
G3-G4 175 (45.0%) 131 (48.5%) 108 (46.0%) 143 (47.4%)
Tumor stage I-II 159 (40.9%) 60 (22.2%) 0.000 52 (22.1%) 0.000 85 (28.1%) 0.000
III-IV 230 (59.1%) 210 (77.8%) 183 (77.9%) 217 (71.9%)
Depth of invasion T1-T2 66 (17.0%) 18 (6.7%) 0.000 16 (6.8%) 0.000 35 (11.6%) 0.000
T3-T4 323 (83%) 252 (93.3%) 219 (93.2%) 267 (88.4%)
Lymph node N0 72 (18.5%) 17 (6.3%) 0.000 15 (6.4%) 0.000 34 (11.3%) 0.000
N1-N3 317 (81.5%) 253 (93.7%) 220 (93.6%) 268 (88.7%)
Distance metastasis M0 235 (60.4%) 121 (44.8%) 0.000 106 (45.1%) 0.000 150 (49.7%) 0.000
M1 154 (39.6%) 149 (55.2%) 129 (54.9%) 152 (50.3%)
CEA (ng/ml) ≤5 243 (62.5%) 149 (55.2%) 0.000 131 (55.7%) 0.000 176 (58.3%) 0.000
>5 146 (37.5%) 121 (44.8%) 104 (44.3%) 126 (41.7%)
CA199 (U/ml) ≤37 278 (71.5%) 175 (64.8%) 0.000 151 (64.3%) 0.000 203 (67.2%) 0.000
>37 111 (28.5%) 95 (35.2%) 84 (35.7%) 99 (32.8%)
NLR <2.36 132 (33.9%) 64 (23.7%) 0.000 54 (23.0%) 0.000 81 (26.8%) 0.000
≥2.36 257 (66.1%) 206 (76.3%) 181 (77.0%) 221 (73.2%)
dNLR <1.85 151 (38.8%) 79 (29.3%) 0.000 68 (28.9%) 0.000 98 (32.5%) 0.000
≥1.85 238 (61.2%) 191 (70.7%) 167 (71.1%) 204 (67.5%)
PLR <132 165 (42.4%) 100 (37.0%) 0.001 83 (35.3%) 0.001 117 (38.7%) 0.002
≥132 224 (57.6%) 170 (63.0%) 152 (64.7%) 185 (61.3%)
LMR <4.95 241 (71.0%) 192 (71.1%) 0.000 173 (73.6%) 0.000 205 (67.9%) 0.000
≥4.95 148 (29.0%) 78 (29.9%) 62 (26.4%) 97 (32.1%)
  1. NLR, neutrophil count to lymphocyte count; dNLR, neutrophil count to (white cell count – neutrophil count); PLR, platelet count to lymphocyte count; LMR, lymphocyte to monocyte ratio.
  2. *Difference between two groups was tested by Kaplan-Meier survival analysis and Log-rank test.
  3. aGrade 1 and 2 stand for high or middle differentiated tumor, grade 3 and 4 stand for poorly differentiated tumor.
  4. bTumor stage according to seventh edition of American Joint of Committee on Cancer.